<?xml version="1.0" encoding="UTF-8"?>
<p>In certain outbreaks, RVF was associated with frequent ocular morbidity [
 <xref rid="B50-viruses-11-00140" ref-type="bibr">50</xref>,
 <xref rid="B51-viruses-11-00140" ref-type="bibr">51</xref>]. Ocular complications have been described for the earlier epidemics of RVF [
 <xref rid="B52-viruses-11-00140" ref-type="bibr">52</xref>,
 <xref rid="B53-viruses-11-00140" ref-type="bibr">53</xref>,
 <xref rid="B54-viruses-11-00140" ref-type="bibr">54</xref>], but it was not studied in the most recent epidemic in South Africa. Two percent is the percentage suffering from retinitis among clinical cases [
 <xref rid="B7-viruses-11-00140" ref-type="bibr">7</xref>]. It cannot be directly deduced that this is the situation with sub-clinical cases as well. In view of the apparent increasing morbidity and mortality associated with RVF [
 <xref rid="B47-viruses-11-00140" ref-type="bibr">47</xref>], the development of a commercial vaccine that is safe for use in humans is highly recommended to permit the immunisation of people in risk occupations [
 <xref rid="B55-viruses-11-00140" ref-type="bibr">55</xref>]. 
</p>
